Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EDP-788 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| EDP-788 | EXPERIMENTAL | Single doses with dose escalation to continue in successive cohorts |
| Placebo | PLACEBO_COMPARATOR | Single dose with matching placebo |
| Name | Type | Description |
|---|---|---|
| EDP-788 | DRUG | EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses |
| Placebo | DRUG | Matching placebo capsules or matching suspension |
Key Inclusion Criteria: * In good general health * BMI between 18 - 32 kg/m2 * Women must be of non-childbearing potential (surgically sterilized) * Normal electrocardiogram * Willing to abstain from strenuous physical exercise starting 3 days prior to admission to the study clinic through the 8 - ...
EDP-788 is an investigational small molecule developed by Enanta Pharmaceuticals, Inc. (ticker ENTA). It has been studied in a Phase 1 clinical trial evaluating safety and pharmacokinetics in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
EDP-788 is being developed by Enanta Pharmaceuticals, Inc., which trades under the ticker symbol ENTA. Enanta is the sponsor of the clinical program for this small molecule candidate.
EDP-788 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational agent and has not been approved by the FDA.
EDP-788 has been evaluated in one completed Phase 1 trial, NCT01999725, titled Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788. The trial enrolled 80 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.
The Phase 1 trial of EDP-788, NCT01999725, was a randomized, double-blind, placebo-controlled study of a single oral dose. It enrolled 80 healthy volunteers aged 18 years and older in the United States and assessed safety and pharmacokinetics. The trial has been completed.